1. Tissue-specific regulatory T cells: biomarker for acute graft-vs-host disease and survival. Engelhardt BG, Sengsayadeth SM, Jagasia M, Savani BN, Kassim AA, Lu P, Shyr Y, Yoder SM, Rock MT, Crowe JE (2012) Exp Hematol 40(12): 974-982.e1
    › Primary publication · 22885125 (PubMed) · PMC3611587 (PubMed Central)
  2. Superior long-term outcome of patients with early transformation of non-Hodgkin lymphoma undergoing stem cell transplantation. Reddy N, Oluwole O, Greer JP, Goodman S, Engelhardt B, Jagasia MH, Savani BN (2012) Clin Lymphoma Myeloma Leuk 12(6): 406-11
    › Primary publication · 22981964 (PubMed) · PMC4845749 (PubMed Central)
  3. Prevalence and risk factors associated with development of ocular GVHD defined by NIH consensus criteria. Jacobs R, Tran U, Chen H, Kassim A, Engelhardt BG, Greer JP, Goodman SG, Clifton C, Lucid C, Vaughan LA, Savani BN, Jagasia M (2012) Bone Marrow Transplant 47(11): 1470-3
    › Primary publication · 22484321 (PubMed)
  4. Predicting posttransplantation diabetes mellitus by regulatory T-cell phenotype: implications for metabolic intervention to modulate alloreactivity. Engelhardt BG, Jagasia SM, Crowe JE, Griffith ML, Savani BN, Kassim AA, Lu P, Weitkamp JH, Moore DJ, Yoder SM, Rock MT, Jagasia M (2012) Blood 119(10): 2417-21
    › Primary publication · 22262764 (PubMed) · PMC3311262 (PubMed Central)
  5. Long-term outcome after autologous or allogeneic stem cell transplantation in patients with recurrent follicular lymphoma. Reddy N, Greer JP, Goodman S, Engelhardt B, Oluwole O, Jagasia MH, Savani BN (2012) Bone Marrow Transplant 47(10): 1318-20
    › Primary publication · 22327132 (PubMed) · PMC4845748 (PubMed Central)
  6. Immunomodulatory nonablative conditioning regimen for B-cell lymphoid malignancies. Chinratanalab W, Reddy N, Greer JP, Morgan D, Engelhardt B, Kassim A, Brandt SJ, Jagasia M, Goodman S, Savani BN (2012) Exp Hematol 40(6): 431-5
    › Primary publication · 22269114 (PubMed) · PMC4067702 (PubMed Central)
  7. Genetic variation in donor CTLA-4 regulatory region is a strong predictor of outcome after allogeneic hematopoietic cell transplantation for hematologic malignancies. Jagasia M, Clark WB, Brown-Gentry KD, Crawford DC, Fan KH, Chen H, Kassim A, Greer JP, Engelhardt BG, Savani BN (2012) Biol Blood Marrow Transplant 18(7): 1069-75
    › Primary publication · 22178694 (PubMed)
  8. Allo-SCT for high-risk AML-CR1 in the molecular era: impact of FLT3/ITD outweighs the conventional markers. Sengsayadeth SM, Jagasia M, Engelhardt BG, Kassim A, Strickland SA, Goodman S, Lucid C, Vnencak-Jones CL, Greer JP, Savani BN (2012) Bone Marrow Transplant 47(12): 1535-7
    › Primary publication · 22659680 (PubMed)
  9. Regulatory T cell expression of CLA or α(4)β(7) and skin or gut acute GVHD outcomes. Engelhardt BG, Jagasia M, Savani BN, Bratcher NL, Greer JP, Jiang A, Kassim AA, Lu P, Schuening F, Yoder SM, Rock MT, Crowe JE (2011) Bone Marrow Transplant 46(3): 436-42
    › Primary publication · 20577222 (PubMed) · PMC3217583 (PubMed Central)
  10. Pretransplantation C-Peptide level predicts early posttransplantation diabetes mellitus and has an impact on survival after allogeneic stem cell transplantation. Griffith ML, Jagasia MH, Misfeldt AA, Chen H, Engelhardt BG, Kassim A, Savani BN, Survant M, Jagasia SM (2011) Biol Blood Marrow Transplant 17(1): 86-92
    › Primary publication · 20561594 (PubMed)